The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from ...

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Rilparencel is ProKidney’s main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We’ll have Rilparencel’s Phase 2 full data in 2025, as ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in SoundHound AI Inc (Symbol: SOUN), where a total volume of 360,873 contracts has ...

The average one-year price target for ProKidney (NasdaqCM:PROK) has been revised to $6.85 / share. This is an increase of 15.10% from the prior estimate of $5.95 dated December 3, 2025. The price ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase II REGEN-007 study evaluating its lead pipeline drug, rilparencel, in ...